AURELIO-04: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF SOT101 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS

被引：1
|
作者：
Champiat, Stephane [1 ]
Marabelle, Aurelien [1 ]
Davar, Diwakar [2 ]
Grell, Peter [3 ]
Ouali, Kaissa [1 ]
Patrikidou, Anna [1 ]
Schoenenberger, Andreu [4 ]
Jelinkova, Lenka Palova [4 ]
Adkins, Irena [4 ]
Tillmanns, Sascha [5 ]
Kiemle-Kallee, Joachim [5 ]
Sachse, Richard [5 ]
Garralda, Elena [6 ]
机构：
[1] Gustave Roussy, Villejuif, France
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Masaryk Mem Canc Inst, Brno, Czech Republic
[4] SOTIO Biotech AS, Prague, Czech Republic
[5] SOTIO Biotech AG, Basel, Switzerland
[6] Vall dHebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0716
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
716
引用
收藏
页码：A749 / A749
页数：1
相关论文
共 50 条
  • [41] A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)
    El Rassi, Fuad A.
    Darbari, Deepika S.
    Burnett, Arthur
    Paulose, Jincy
    Laine, Dramane I.
    Purkayastha, Das
    Kato, Gregory J.
    BLOOD, 2019, 134
  • [42] Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study
    Neutel, Joel M.
    Giles, Thomas D.
    Punzi, Henry
    Weiss, Robert J.
    Li, Huiling
    Finck, Amy
    JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (12) : 915 - 920
  • [43] MetaPHER: A phase IIlb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer
    Kummel, S.
    Crepelle-Flechais, A.
    Schlegel, M.
    Hillenbach, C.
    Swat, A.
    Franz, M.
    Girase, P.
    Schneider, A.
    Heinzmann, D.
    Shing, M.
    CANCER RESEARCH, 2016, 76
  • [44] A single-arm, open-label, multi-center, phase I study of HA121-28 in patients with advanced solid tumors
    Zhao, H.
    Wei, X.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Ma, Y.
    Chen, L.
    Chen, D.
    Wang, F.
    Peng, R.
    Liu, Q.
    Xu, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S1018 - S1018
  • [45] Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study
    Wei, Xiaoting
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Tian, Hongqi
    Jia, Zhongwei
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [47] Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
    Sadayoshi Ito
    Naoki Kashihara
    Kenichi Shikata
    Masaomi Nangaku
    Takashi Wada
    Yasuyuki Okuda
    Tomoko Sawanobori
    Clinical and Experimental Nephrology, 2021, 25 : 1070 - 1078
  • [48] Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
    Ito, Sadayoshi
    Kashihara, Naoki
    Shikata, Kenichi
    Nangaku, Masaomi
    Wada, Takashi
    Okuda, Yasuyuki
    Sawanobori, Tomoko
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (10) : 1070 - 1078
  • [49] AN OPEN LABEL PHASE IA/IB STUDY FOR SAFETY, PHARMACOKINETICS (PK), AND EFFICACY OF ONC 392 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADVANCED SOLID TUMORS
    Zheng, Pan
    He, Kun
    Liu, Yang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A564 - A564
  • [50] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Brose, Marcia S.
    Cohn, Allen L.
    Mier, James
    Di Simone, Christopher
    Hyman, David M.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Schmidt, Emmett V.
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Aghajanian, Carol
    Taylor, Matthew
    LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
12345